Company news

Algorae Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Quarterly Activities Report/Appendix 4C Cash Flow Statement

January 29, 2024

Agreement with HL Pharma Addendum

January 4, 2024

Algorae to list existing Option series on ASX

December 5, 2023

1AI commences AI-168 pre-clinical studies

November 22, 2023

Addendum to September Quarterly Report

November 21, 2023

CSIRO Grant for Artificial Intelligence Platform

October 30, 2023

Quarterly Activities/Appendix 5B Cash Flow Report

October 26, 2023

LCT commences AI-116 pre clinical studies

August 31, 2023

Quarterly Activities/Appendix 4C Cash Flow Report

July 27, 2023

Patent application over AI-116 for Dementia filed

July 25, 2023

LCT Announces Shortfall Completion Notice

May 3, 2023

Rights Issue Prospectus

March 20, 2023

APeT Cleansing Announcement

March 10, 2023

Pause in Trading

March 10, 2023

LCT Undertakes $2.5 Million Capital Raise Initiative

February 28, 2023

Half Year Accounts and Appendix 4D

February 27, 2023

Trading Halt

February 26, 2023

Quarterly Activity Report and Appendix 4C

October 28, 2022

New milestone for LCTs AI development

September 16, 2022

Preliminary Final Report and 2022 Financial Statements

August 31, 2022

LCT Completes Strategic A$1.285M Placement

May 30, 2022

Half Yearly Report and Accounts

February 25, 2022

LCT Signs Service Agreement with NZeno

January 23, 2022

Results of Rights Issue

December 28, 2021

Extension of Rights Issue

December 8, 2021

Prospectus- Rights Issue

November 14, 2021

LCT- Rights Issue

November 14, 2021

LCT Receives New Zealand R&D Tax Credit

November 9, 2021

LCT Advises Price Change for Rights Issue

November 7, 2021

LCT Signs MOU with NZeno, Secures Pig Cells for NTCELL Trial

October 26, 2021

Secures Funds for 3rd Trial of NTCELL in Parkinson Disease

October 18, 2021

Preliminary Final Report and 2021 Financial Statements

August 31, 2021

LCT Interim CEO Appointed

July 15, 2021

LCT exits peptide projects

March 28, 2021

LCT CEO Dr Ken Taylor signals intention to retire

January 25, 2021

Preliminary Final Report and 2020 Financial Statements

August 31, 2020

Amended Appendix 4C

July 30, 2020

Response to ASX Aware Query

July 12, 2020

Appendix 4C - quarterly

April 29, 2020

LCT extends cash runway with receipt from Vertex acquisition

October 15, 2019

LCT to benefit from Semma Therapeutics acquisition by Vertex

September 18, 2019

Preliminary Final Report and 2019 Financial Statements

August 29, 2019

NTCELL Parkinsons trial patient data 2 years after implant

May 12, 2019

NTCELL Parkinsons trial patient data at 18 months

November 1, 2018

Preliminary Final Report and 2018 Financial Statements

August 30, 2018

NTCELL and Parkinsons trial update

May 14, 2018

LCT Strategy Update

April 11, 2018

LCT to sell JV Shares and receive DIABECELL licence

January 25, 2018

Appendix 4C - Quarterly

January 23, 2018

Results of LCT Parkinsons trial require further analysis

November 9, 2017

← Newer news releases · Older news releases →

Decks